BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30

• Drug Development

  ASCO2016: Mylan-BioCon’s Biosimilar Cancer Drug Comparable to Roche’s Herceptin

  June 6, 2016

   · 

  10 min read
• Drug Development

  ASCO2016: Celator Pharma Presented Phase 3 Trial Results In Patients With High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival

  June 6, 2016

   · 

  9 min read
• Drug Development

  ASCO2016: Kite Pharma/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma

  June 6, 2016

   · 

  4 min read
• Drug Development

  ASCO2016: Early-Phase Immuno-Oncology Studies Of Eli Lilly’s ALIMTA (Pemetrexed) And CYRAMZA (Ramucirumab) With Merck & Co.'s KEYTRUDA (Pembrolizumab) Show Encouraging Results In Non-Small Cell Lung Cancer

  June 6, 2016

   · 

  23 min read
• Drug Development

  ASCO2016: AbbVie Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeti

  June 6, 2016

   · 

  13 min read
• Drug Development

  Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

  June 6, 2016

   · 

  7 min read
• Drug Development

  Novartis AG Pivotal Data For Tafinlar + Mekinist Demonstrated A 63 Percent Overall Response Rate In Treating Rare Form Of Lung Cancer

  June 6, 2016

   · 

  19 min read
• Pharm Country

  Palatin Tech Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property

  June 6, 2016

   · 

  3 min read
• Drug Development

  ASCO2016 : AbbVie Presents Encouraging Phase 1 Data For Investigational Medicine ABT-414 As Monotherapy In Patients With An Aggressive Brain Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting

  June 6, 2016

   · 

  8 min read
• Pharm Country

  ASCO2016: Novartis Pharmaceuticals Corporation Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-Free Remission (TFR) After Stopping Tasigna

  June 6, 2016

   · 

  18 min read